215 related articles for article (PubMed ID: 19524477)
21. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
22. Hallucinations in Parkinson's disease: a follow-up study.
de Maindreville AD; Fénelon G; Mahieux F
Mov Disord; 2005 Feb; 20(2):212-7. PubMed ID: 15390044
[TBL] [Abstract][Full Text] [Related]
23. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
Devos D;
Mov Disord; 2009 May; 24(7):993-1000. PubMed ID: 19253412
[TBL] [Abstract][Full Text] [Related]
24. The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study.
Geerligs L; Meppelink AM; Brouwer WH; van Laar T
Clin Neuropharmacol; 2009; 32(5):266-8. PubMed ID: 19667979
[TBL] [Abstract][Full Text] [Related]
25. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
[TBL] [Abstract][Full Text] [Related]
26. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
27. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
Garcia Ruiz PJ
Mov Disord; 2006 May; 21(5):727-8. PubMed ID: 16547919
[No Abstract] [Full Text] [Related]
28. Drug for "off" episodes of Parkinson's--effective but limited.
Mayo Clin Health Lett; 2005 Jul; 23(7):4. PubMed ID: 16189845
[No Abstract] [Full Text] [Related]
29. New drug helps Parkinson's "off" periods.
Health News; 2004 Jul; 10(7):2. PubMed ID: 15239150
[No Abstract] [Full Text] [Related]
30. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
31. Assessment of hallucinations in Parkinson's disease using a novel scale.
Wada-Isoe K; Ohta K; Imamura K; Kitayama M; Nomura T; Yasui K; Nakaso K; Nakashima K
Acta Neurol Scand; 2008 Jan; 117(1):35-40. PubMed ID: 18095953
[TBL] [Abstract][Full Text] [Related]
32. Continuous subcutaneous apomorphine infusion in Parkinson's disease.
Simpkin DM; Milner R; Snell AP
Med J Aust; 1992 Jun; 156(12):883-4. PubMed ID: 1603020
[No Abstract] [Full Text] [Related]
33. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
34. The pragmatic use of apomorphine at the end of life.
Dewhurst F; Lee M; Wood B
Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
[TBL] [Abstract][Full Text] [Related]
35. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
[TBL] [Abstract][Full Text] [Related]
36. Apomorphine infusion for improving sleep in Parkinson's disease.
Chaudhuri KR; Leta V
Lancet Neurol; 2022 May; 21(5):395-398. PubMed ID: 35429469
[No Abstract] [Full Text] [Related]
37. [Effect of apomorphine on the bladder of parkinsonian patients].
Aranda B; Cramer P; Adba MA
J Urol (Paris); 1992; 98(1):25-9. PubMed ID: 1527394
[TBL] [Abstract][Full Text] [Related]
38. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Soykan I; Sarosiek I; Shifflett J; Wooten GF; McCallum RW
Mov Disord; 1997 Nov; 12(6):952-7. PubMed ID: 9399220
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
Grandas F
Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
[TBL] [Abstract][Full Text] [Related]
40. Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.
Bhidayasiri R; Boonpang K; Jitkritsadakul O; Calne SM; Henriksen T; Trump S; Chaiwong S; Susang P; Boonrod N; Sringean J; van Laar T; Drent M; Chaudhuri KR
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S49-S55. PubMed ID: 27939324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
